Robert P Giugliano MD

Preventive Cardiology, Cardiac Critical Care

Cardiovascular Medicine Brigham and Women's Hospital

TIMI Study Office, Hale BTM Suite 7022, 60 Fenwood RoadBrigham And Womens Hospital Cardiovascualar DivisionBoston, MA 02115
Phone+1 617-278-0317
Fax+1 617-264-5130

Dr. Giugliano is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Giugliano's full profile Already have an account?

Summary

Dr. Robert Giugliano is a cardiologist based in Boston, MA, with subspecialties in preventive cardiology and cardiac critical care. He completed his medical education at Harvard Medical School in 1989, followed by a residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in cardiovascular disease at Massachusetts General Hospital. His clinical experience encompasses fields such as general cardiology, acute coronary syndrome, myocardial infarction, sarcoidosis-related cardiomyopathy, and atrial fibrillation. Dr. Giugliano has multiple publications focused on cardiovascular health, including studies on blood pressure variability and cholesterol management. He is recognized as a Fellow of the American College of Cardiology.

Education & Training

Mass General Brigham/Massachusetts General HospitalFellowship, Cardiovascular Disease, 1993 - 1996
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1989 - 1993
Harvard Medical SchoolClass of 1989

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1990 - Present
MA State Medical License 1993 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017

Publications & Presentations

PubMed

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study.
Andre M Small, Siddharth M Patel, Robert P Giugliano, David A Morrow, Erica L Goodrich
Blood. 2026-08-06
Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis.
Deborah M Siegal, Marc Carrier, M Cecilia Bahit, Jackie Bosch, Alexander P Benz
Circulation. 2026-08-04
Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.
Lawrence A Leiter, Robert P Giugliano, Nicholas A Marston, Gaetano De Ferrari, Jose C Nicolau
Diabetes Care. 2026-08-01

Journal Articles

Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction with Statins, Ezetimibe, and PCSK9 Inhibition
Robert P Giugliano, Marc S Sabatine, JAMA Cardiology
Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin Therapy
Prakash Deedwania, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial Infarction
Christopher E Kurtz, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology

Authored Content

Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020

Press Mentions

Is Warfarin Still an Option for Frail Patients with Atrial Fibrillation?August 30th, 2025
Frail Older Patients with AF May Fare Better Switching to DOACAugust 5th, 2025
Elderly ASCVD Patients Benefit from Aggressive LDL-Lowering with EvolocumabFebruary 5th, 2025